Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 800,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 800,000 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the completion of the transaction, the director directly owned 13,701,546 shares in the company, valued at approximately $473,388,414.30. This trade represents a 5.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Daniel Allen Gold also recently made the following trade(s):

• On Tuesday, June 30th, Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock. The stock was sold at an average price of $35.28, for a total value of $436,766.40.
• On Friday, June 26th, Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock. The shares were sold at an average price of $34.00, for a total value of $21,276,622.00.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $35.39 on Wednesday. The stock has a market capitalization of $25.45 billion, a P/E ratio of -58.98 and a beta of 1.13. The company has a 50 day moving average price of $29.88 and a 200 day moving average price of $27.02. Roivant Sciences Ltd. has a fifty-two week low of $10.70 and a fifty-two week high of $35.90.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The company had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. During the same quarter in the prior year, the business earned ($0.29) EPS. On average, research analysts forecast that Roivant Sciences Ltd. will post -1.83 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. TD Asset Management Inc grew its stake in Roivant Sciences by 94.7% in the third quarter. TD Asset Management Inc now owns 316,200 shares of the company’s stock valued at $4,784,000 after purchasing an additional 153,800 shares in the last quarter. HighVista Strategies LLC lifted its holdings in shares of Roivant Sciences by 61.4% during the 3rd quarter. HighVista Strategies LLC now owns 98,858 shares of the company’s stock valued at $1,496,000 after buying an additional 37,590 shares during the last quarter. Pictet Asset Management Holding SA lifted its holdings in shares of Roivant Sciences by 790.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock valued at $50,180,000 after buying an additional 2,052,693 shares during the last quarter. Neo Ivy Capital Management grew its stake in shares of Roivant Sciences by 229.6% in the 3rd quarter. Neo Ivy Capital Management now owns 237,392 shares of the company’s stock valued at $3,592,000 after buying an additional 165,362 shares in the last quarter. Finally, Capricorn Fund Managers Ltd grew its stake in shares of Roivant Sciences by 124.4% in the 4th quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock valued at $9,667,000 after buying an additional 247,000 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

ROIV has been the topic of a number of research reports. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Citigroup increased their target price on shares of Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Finally, Sanford C. Bernstein initiated coverage on Roivant Sciences in a report on Friday, March 20th. They set an “outperform” rating and a $35.00 price target on the stock. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.